Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Sexually transmitted disease surveillance 2002 supplement; Gonococcal Isolate Surveillance Project (GISP) annual report, 2002
  • Published Date:
    October 2003
Filetype[PDF-3.79 MB]

  • Alternative Title:
    Gonococcal Isolate Surveillance Project (GISP) annual report, 2002 ; GISP 2002 surveillance supplement ;
  • Personal Author:
  • Description:
    Introduction and overview -- Demographic and clinical data -- Susceptibility data -- Non-GISP susceptibility reporting -- Addtional resources -- References -- Project figures -- Clinic-specific demographic, clinical, and laboratory data.

    "With 351,852 gonorrhea cases reported in 2002, gonorrhea is the second most frequently reported communicable disease in the United States. Gonorrhea rates in the United States declined 73.8% during 1975-1997. After a small increase in the rate in 1998, the gonorrhea rate decreased slightly and the 2002 rate was 125.0 cases per 100,000 persons. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, data suggest that gonorrhea facilitates HIV transmission. The treatment and control of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop resistance to antimicrobial agents. The appearance of penicillinase-producing N. gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The current CDC-recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins (ceftriaxone and cefixime), and three fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). However, since the 1990s, fluoroquinolone-resistant N. gonorrhoeae (QRNG) have been reported from many parts of the world, including the United States. The increased prevalence of QRNG in Asia (where prevalence in several countries exceeds 40%13), the Pacific Islands, Hawaii, and California, prompted CDC to recommend that fluroquinolones not be used to treat patients with gonorrhea acquired in these areas with high QRNG prevalence." -- p. 1.

  • Content Notes:
    prepared by Susan A. Wang, Alesia B. Harvey, Susan M. Conner, and LuEtta Schneider. ; Includes bibliographical references (p. 10-12). ;
  • Document Type:
  • Place as Subject:
  • Main Document Checksum:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: